^
PBRM1 mutation
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
Eur Urol - 2 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
sunitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pazopanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
cabozantinib capsule
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
nivolumab + cabozantinib tablet
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
RCC
pembrolizumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
tivozanib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
Clear Cell Renal Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
MET amplification
RCC
savolitinib
Sensitive: A2 - Guideline
ESMO.org - 3 weeks
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
PD-L1 expression
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
RCC
avelumab + axitinib
Sensitive: A1 - Approval
No biomarker
RCC
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
sorafenib
Sensitive: A1 - Approval
No biomarker
RCC
tivozanib
Sensitive: A1 - Approval
No biomarker
RCC
temsirolimus
Sensitive: A1 - Approval
No biomarker
RCC
sunitinib
Sensitive: A1 - Approval
No biomarker
RCC
everolimus + lenvatinib
Sensitive: A1 - Approval
No biomarker
RCC
everolimus
Sensitive: A1 - Approval
No biomarker
RCC
bevacizumab + pegylated interferon α -2a
Sensitive: A1 - Approval
No biomarker
RCC
cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
No biomarker
RCC
pembrolizumab + axitinib
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
Sensitive: A1 - Approval
No biomarker
RCC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + ipilimumab
Sensitive: A1 - Approval
No biomarker
RCC
axitinib
Sensitive: A1 - Approval
No biomarker
RCC
pazopanib
Sensitive: A1 - Approval
No biomarker
RCC
aldesleukin
Sensitive: A1 - Approval
No biomarker
RCC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
RCC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
VHL mutation
RCC
belzutifan
Sensitive: A1 - Approval
No biomarker
RCC
bevacizumab
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab + pegylated interferon α -2a
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
avelumab + axitinib
Sensitive: A2 - Guideline
No biomarker
RCC
bevacizumab + erlotinib
Sensitive: A2 - Guideline
No biomarker
RCC
erlotinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
temsirolimus
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
sorafenib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
lenvatinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
axitinib
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
everolimus
Sensitive: A2 - Guideline
No biomarker
Clear Cell Renal Cell Carcinoma
bevacizumab
Sensitive: A2 - Guideline
PD-L1 expression
Clear Cell Renal Cell Carcinoma
pembrolizumab + axitinib
Sensitive: B - Late Trials
PD-L1 expression
RCC
nivolumab + cabozantinib tablet
Sensitive: B - Late Trials
MET mutation
RCC
savolitinib
Sensitive: B - Late Trials
No biomarker
RCC
belzutifan
Sensitive: B - Late Trials
PD-L1 expression
RCC
pembrolizumab + axitinib
Sensitive: B - Late Trials
PD-L1 expression
RCC
bevacizumab + atezolizumab
Sensitive: B - Late Trials
ARID1A mutation
RCC
sunitinib
Sensitive: B - Late Trials
MTOR mutation
RCC
sunitinib
Sensitive: B - Late Trials
ROBO3 mutation
RCC
sunitinib
Sensitive: B - Late Trials
FLT1 rs9554320
RCC
sunitinib
Sensitive: B - Late Trials
KDR rs2071559
RCC
sunitinib
Sensitive: B - Late Trials
PD-L1 expression
RCC
nivolumab + ipilimumab
Sensitive: B - Late Trials
AXL-L
RCC
cabozantinib tablet
Sensitive: B - Late Trials
MSI-H/dMMR
RCC
dostarlimab
Sensitive: C1 - Off-label
VHL mutation
Clear Cell Renal Cell Carcinoma
belzutifan
Sensitive: C1 - Off-label
PD-L1 expression
RCC
atezolizumab
Sensitive: C1 - Off-label
BRCA1 mutation
RCC
olaparib
Sensitive: C1 - Off-label
BRCA2 mutation
RCC
olaparib
Sensitive: C1 - Off-label
PD-L1 expression
RCC
pembrolizumab
Sensitive: C1 - Off-label
VHL mutation
Clear Cell Renal Cell Carcinoma
PT2385
Sensitive: C2 – Inclusion Criteria
MTOR mutation
RCC
everolimus
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
RCC
avelumab
Sensitive: C2 – Inclusion Criteria
MET amplification
RCC
crizotinib
Sensitive: C2 – Inclusion Criteria
KIM1 expression
RCC
CDX-014
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
RCC
nivolumab
Sensitive: C2 – Inclusion Criteria
FLCN mutation
RCC
everolimus
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
RCC
bevacizumab + albumin-bound paclitaxel + IPI-549
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
RCC
bevacizumab + atezolizumab + IPI-549
Sensitive: C2 – Inclusion Criteria
MET mutation
RCC
cabozantinib capsule
Sensitive: C2 – Inclusion Criteria
TFE3 translocation
RCC
cabozantinib tablet
Sensitive: C2 – Inclusion Criteria
MET mutation
RCC
crizotinib
Sensitive: C2 – Inclusion Criteria
HDAC2 expression
RCC
pazopanib + CG-781
Sensitive: C3 – Early Trials
PBRM1 underexpression
RCC
sorafenib
Resistant: C3 – Early Trials
PBRM1 overexpression
RCC
sorafenib
Sensitive: C3 – Early Trials
PD-1-H
RCC
sunitinib
Resistant: C3 – Early Trials
SETD2 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Resistant: C3 – Early Trials
ERVE-4 expression
Clear Cell Renal Cell Carcinoma
nivolumab
Sensitive: C3 – Early Trials
HAVCR2 expression
RCC
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
HAVCR2 expression
RCC
nivolumab
Sensitive: C3 – Early Trials
VEGFA-H
RCC
pazopanib
Resistant: C3 – Early Trials
CXCL12-H
RCC
pazopanib
Resistant: C3 – Early Trials
SPP1-L
RCC
pazopanib
Sensitive: C3 – Early Trials
HGF-L
RCC
pazopanib
Sensitive: C3 – Early Trials
CXCL8-L
RCC
pazopanib
Sensitive: C3 – Early Trials
IL6-L
RCC
pazopanib
Sensitive: C3 – Early Trials
PAI1-H
RCC
axitinib
Resistant: C3 – Early Trials
HGF expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
IL18 expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
ANGPT2 expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
TIMP1 expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
CSF1 expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
VEGFA expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
CXCL9 expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
IL18BP expression
RCC
lenvatinib
Sensitive: C3 – Early Trials
SYNE1 mutation
Clear Cell Renal Cell Carcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
RCC
pembrolizumab + lenvatinib
Sensitive: C3 – Early Trials